Non–cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes. The symptoms and clinical course of NCFB are variable.
Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily. The classic clinical manifestations of this clinical condition are cough and daily mucopurulent sputum production, often lasting months to years. Blood-streaked sputum or hemoptysis may result from airway damage associated with acute infection. Dyspnea and wheezing occur in 75% of patients. Pleuritic chest pain occurs in 50% of patients and reflects the presence of distended peripheral airways or distal pneumonitis adjacent to a visceral pleural surface. Physical examination of the chest shows adventitious breath sounds, such as crackles (70%), wheezing (34%) or rhonchi (44%).
What are the Non-Cystic Fibrosis Bronchiectasis Emerging Drugs?
Brensocatib: Insmed Incorporated
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Cystic Fibrosis Bronchiectasis (NCFB).
CSL787: CSL Behring
It is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease.
DelveInsight's "Non Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Non Cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non Cystic Fibrosis Bronchiectasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Non Cystic Fibrosis Bronchiectasis market report provides current treatment practices, emerging drugs, Non Cystic Fibrosis Bronchiectasis market share of the individual therapies, current and forecasted Non Cystic Fibrosis Bronchiectasis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Non Cystic Fibrosis Bronchiectasis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Non Cystic Fibrosis Bronchiectasis market.
The DelveInsight’s Non Cystic Fibrosis Bronchiectasis market report gives a thorough understanding of the Non Cystic Fibrosis Bronchiectasis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
The drug chapter segment of the Non Cystic Fibrosis Bronchiectasis report encloses the detailed analysis of Non Cystic Fibrosis Bronchiectasis marketed drugs and late-stage (Phase-III and Phase-II) Non Cystic Fibrosis Bronchiectasis pipeline drugs. It also helps to understand the Non Cystic Fibrosis Bronchiectasis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The report provides the details of the marketed products/off-label treatments available for Non Cystic Fibrosis Bronchiectasis treatment. The report provides the details of the emerging therapies under the late and mid-stage of development for Non Cystic Fibrosis Bronchiectasis treatment.
The Non Cystic Fibrosis Bronchiectasis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Non Cystic Fibrosis Bronchiectasis market trends by analyzing the impact of current Non Cystic Fibrosis Bronchiectasis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Non Cystic Fibrosis Bronchiectasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Non Cystic Fibrosis Bronchiectasis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
This section focuses on the rate of uptake of the potential Non Cystic Fibrosis Bronchiectasis drugs recently launched in the Non Cystic Fibrosis Bronchiectasis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Non Cystic Fibrosis Bronchiectasis market uptake by drugs; patient uptake by therapies; and sales of each drug. Non Cystic Fibrosis Bronchiectasis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Non Cystic Fibrosis Bronchiectasis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pediatric Growth Hormone Deficiency Market Report Scope
· The report covers the descriptive overview of Non Cystic Fibrosis Bronchiectasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Non Cystic Fibrosis Bronchiectasis epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Non Cystic Fibrosis Bronchiectasis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of the Non Cystic Fibrosis Bronchiectasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non Cystic Fibrosis Bronchiectasis market
Pediatric Growth Hormone Deficiency Market Report Highlights
· In the coming years, the Non Cystic Fibrosis Bronchiectasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
· The companies and academics are working to assess challenges and seek opportunities that could influence Non Cystic Fibrosis Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
· Major players are involved in developing therapies for Non Cystic Fibrosis Bronchiectasis. The launch of emerging therapies will significantly impact the Non Cystic Fibrosis Bronchiectasis market
· A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Non Cystic Fibrosis Bronchiectasis
· Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Comments